RBC Capital lowered the firm’s price target on Hookipa Pharma (HOOK) to $48 from $50 and keeps an Outperform rating on the shares. Hookipa Pharma and its new management are well-positioned to focus on getting AVALON-1 off the ground with enrollment wrapped up in the phase II portion of the ongoing study in HPV16+ patients, the analyst tells investors in a research note. Recent updates are supportive of the promising efficacy and safety profile seen with eseba-vec, RBC says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOOK:
- Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
- Hookipa Pharma reports Q3 EPS ($1.10), consensus ($1.90)
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Is HOOK a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
